MedTrace Logo

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

NCT02801435 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-07-17

No results posted yet for this study

Summary

This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.

Conditions

Interventions

DRUG

0.5% Icotinib hydrochloride cream

Topical administration for twice daily

DRUG

1.0% Icotinib hydrochloride cream

Topical administration for twice daily

DRUG

2.0% Icotinib hydrochloride cream

Topical administration for twice daily

DRUG

4.0% Icotinib hydrochloride cream

Topical administration for twice daily

DRUG

Placebo

Topical administration for twice daily

Sponsors & Collaborators

  • Tigermed Consulting Co., Ltd

    collaborator INDUSTRY

  • Betta Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min Zheng · The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU)

  • Zourong Ruan · The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-17
Primary Completion
2017-06-08
Completion
2017-06-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02801435 on ClinicalTrials.gov